EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.

View source ↗

Summary

Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic arthritis, ulcerativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Arthritis
• Crohn Disease
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Amgevita (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Colitis, Ulcerative;Arthritis, Juvenile Rheumatoid;Spondylitis, Ankylosing;Psoriasis;Crohn Disease;Arthritis, Rheumatoid. MAH: Amgen Europe B.V.. Decision date: 13/08/2026